CONTEXT: An opinion piece on why more RWE is needed on how patients respond to biosimilars in oncology | “More evidence is the tool for persuading oncology providers to switch Continue Reading
CONTEXT: Report of data presented at the EuroPCR annual meeting on Medtronic’s Symplicity Renal Denervation system. Results from a registry involving nearly 3,000 patients showed significant and clinically meaningful reductions Continue Reading
CONTEXT: Report of a study published in the Annals of Hematology detailing the use of RWE to conduct a head-to-head comparison of treatments used in relapsed/refractory multiple myeloma. Retrospective analysis Continue Reading
CONTEXT: More evidence of the increasing focus on RWE, with Aetion securing another significant round of funding. The company reports doubling of revenues last year and is planning to expand Continue Reading
CONTEXT: Despite the headline news that RWE shows no real improvement for mesothelioma patients, if you get down to the end of the article, there is promising news with the Continue Reading
CONTEXT: Presentation of RWD on Mavacamten in obstructive hypertrophic cardiomyopathy by MS at the ACC annual scientific session being held virtually this year. BMS following an increasing trend od presenting Continue Reading
CONTEXT: As the parent of a son who is still undiagnosed but probably has a Fragile X like syndrome, this news is extremely heartening. To see Real-World Data being used Continue Reading
CONTEXT: Another RWR study showing deficiencies in available biomarker testing, this time in Chronic lymphatic leukaemia patients. Biomarker driven care will give better outcomes for those patients with specific mutations Continue Reading
CONTEXT: Publication of an RWR study in rheumatoid arthritis showing equivalent safety profile between a biologic DMARD and an oral Janus kinase inhibitor. IMPACT: Low READ TIME: 2 mins Continue Reading
CONTEXT: A proper peer reviewed study article on a retrospective study based on an oncology registry in Canada highlighting the differences in outcomes for rural versus urban patients. READ TIME: Continue Reading
